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Abstract: Background: Despite the high rate of postoperative recurrence 
(POR) in Crohn's disease (CD), there is no widely accepted consensus on 
its prevention. 
Aim: To compare the efficacy of biological and conventional therapies in 
preventing POR of CD. 
Methods: We searched four electronic databases up to April 2019 for 
articles that examined the efficacy of different preventive therapies 
against POR. Our PICO was: (P) adults with CD who underwent intestinal 
resection, (I) biological agents, (C) conventional therapies or a 
placebo, and (O) clinical, endoscopic, and histological POR.  
Results: Anti-TNFα agents were significantly better in preventing 
clinical, endoscopic, severe endoscopic and histological POR compared to 
conventional therapies (OR: 0.508, 95% CI: 0.309-0.834, P = 0.007; OR: 
0.312, 95% CI: 0.199-0.380, P < 0.001; OR: 0.195, 95% CI: 0.107-0.356, P 
< 0.001; and OR: 0.255, 95% CI: 0.106-0.611, P = 0.002, respectively), as 
well as in the subgroup of nonselected CD patients (OR: 0.324, 95% CI: 
0.158-0.664, P = 0.002; OR: 0.225, 95% CI: 0.124-0.409, P < 0.001; and 
OR: 0.248, 95% CI: 0.070-0.877, P = 0.031, respectively). Infliximab and 
adalimumab proved to be equally effective in preventing endoscopic POR. 
Conclusion: Anti-TNFα agents are more effective in preventing clinical, 
endoscopic and histological POR than conventional therapies, even in 
nonselected CD patients.  
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REVIEWERS' COMMENTS TO THE AUTHOR: 
Reviewer #1: The article entitled "Anti-TNF<alpha> agents are the best choice in preventing 
postoperative Crohn's disease: a meta-analysis" by Adirenn Eros et al. is a meta-analysis 
aimed to compare the efficacy of anti-TNF agents and conventional therapy in preventing 
POR in patients with CD.  The main result is that TNF antagonists resulted to be the best 
drugs in this regards. Moreover, the authors performed a head-to-head comparison between 
ADA and IFX by using non-RCT data and they found that the efficacy of these two anti-
TNF<alpha> agents is nearly the same. Finally, and interestingly, they concluded that it is 
unnecessary to select patients after intestinal resection based on risk factors because both 
high-risk patients and unselected patients benefit from early prophylactic anti-TNF therapy 
postoperatively.  
Overall, the manuscript is well written and the analysis well performed. The strengths of this 
study are: a high number (709) of CD patients evaluated; an update of the literature with 
regards to POR compared to the previous systematic reviews with meta-analysis published in 
2015 and 2016; most of the included trials were RCTs (8/10); in addition to the comparison 
analysis between anti-TNF and conventional drugs, a comparative analysis between ADA and 
IFX was performed. The main limitations are: the inclusion on the same analysis data from 
RCT and data from retrospective/observational studies; the variability of the follow up period 
among the studies (6-36 months). I have additional suggestions: 
 
- Methods: It is unclear the nature of the two observational studies in the comparison analysis 
between ADA and IFX (prospective? retrospective?). This data can only be seen from Table I. 
Please, add this information to the text.  
Thank you for this comment. We added the information required to the ‘Characteristics of the 
included studies’ section of the manuscript.   
 
- Results. The manuscript would be more interesting if data on Vedolizumab have been 
considered for the comparative analysis (The Use of Vedolizumab in Preventing 
Postoperative Recurrence of Crohn's Disease. Yamada A, Komaki Y, Patel N, Komaki F, 
Pekow J, Dalal S, Cohen RD, Cannon L, Umanskiy K, Smith R, Hurst R, Hyman N, Rubin 
DT, Sakuraba A. Inflamm Bowel Dis. 2018 Feb 15;24(3):502-509) 
Thank you for this valuable comment. In order to capture all the latest literature, we added not 
only the recommended ‘vedolizumab’ to the search strategy, but also other possible biological 
drugs used in IBD treatment, namely, certolizumab, golimumab and ustekinumab. This 
*Response to Reviewers
Manuscript number: DLD-19-148 
updated search identified four additional studies: three studies with anti-TNF-alpha were 
eligible for quantitative analysis and, unfortunately, only one study was available with 
vedolizumab [Yamada et al.]. We were unable to use the data of the vedolizumab-treated 
group of the Yamada study in our analysis due to several reasons: (1) the number of patients 
in this study group was very low; (2) we did not find any other studies that evaluated the 
efficacy of vedolizumab versus conventional therapies in preventing POR, so that this result 
would have stood alone in a separate subgroup; and (3) the comparator group was the same 
for the vedolizumab- and the anti-TNF-alpha-treated groups as well (the thiopurine-treated 
group) while it is not allowed to use the data of the same study group twice in a meta-analysis 
(due to overrepresentation). Based on the above-mentioned, we decided to use the data of the 
anti-TNF-alpha- and thiopurine-treated groups from the study of Yamada in the updated 
statistical analysis. The results of the original study regarding vedolizumab were interpreted in 
the discussion section of the manuscript. 
Thanks to the extended search, histological POR and safety profile of the applied 
treatment modalities became processable in meta-analysis. 
 
Reviewer #2: In this meta-analysis by Adrienn Eros and and colleagues, the authors aimed to 
compare the efficacy of anti-TNF<alpha> agents and conventional therapy in preventing POR 
of CD. In summary, the pooling of the included studies showed that anti-TNF<alpha> agents 
are more effective in preventing clinical and endoscopic POR than conventional therapies, 
both in unselected and high-risk CD patients, without significant heterogeneity, and that there 
was no significant difference between IFX and ADA.  
As also stated by the authors in the discussion, this is a hot topic, which has been repeatedly 
approached through multiple meta-analyses and a Cochrane review in recent years. Therefore, 
the novelty of this paper is not very robust. Anyway, search strategy and eligibility criteria, 
data extraction and study quality evaluation (through the Cochrane Risk of Bias Tool for 
RCTs, and the Newcastle-Ottawa scale for observational studies) are correct for the purpose 
of the meta-analysis, and the methodology of this study has sufficient overall quality. 
However, other strategies of analysis could be applied to improve the strength of the results.  
 
In particular, even if the number of the included studies is quite low, a meta-regression with 
the variables extracted from each study could be performed.  
Thank you for this comment. When comparing the efficacy of anti-TNFα treatment and 
thiopurines in preventing clinical and endoscopic POR, we complemented the analysis with 
Manuscript number: DLD-19-148 
meta-regressions. The results are summarized in the Results section under subheading 
‘Comparison of preventive anti-TNFα versus conventional therapy for POR’. Graphs of the 
meta-regressions are presented in Supplementary Appendix (Supplementary figures 4 and 5). 
 
Furthermore, I believe that interesting findings could be obtained by exploring the effects on 
the outcomes of the study (with subgroup or meta-regression analysis) by adding another 
relevant patient-level variable: the previous medical history, particularly being naïve or not to 
anti-TNFs.  
Thank you for this comment. We attempted to perform a comparison based on this 
recommendation but, unfortunately, we were unable to make subgroup analysis according to 
patient characteristics (e.g., smoking, disease duration, gender, disease behavior). The studies 
reported only overall descriptive statistics of the included patients and failed to report data by 
treatment subgroups separately. Similarly, no adjusted analyses were reported. 
The POR rate in patients not naïve to anti-TNF-alpha was reported in only three 
studies (Auzolle, Kotze and Regueiro 2016). We could only examine how the preoperatively 
given anti-TNF-alpha treatment affected the rate of POR. According to our analysis, the 
preoperative use of anti-TNF alpha agents did not affect significantly the rate of POR [OR 
1.021, 95% CI 0.490-2.128; p = 0.956 (I
2 
= 69.8%; p=0.036), with the fixed effect model].  
The effect of preventive treatment with biologics after operation could not be examined 
because we were lacking data regarding subgroups by preoperative treatment. 
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Minor points: 
- Introduction is too long and needs to be shortened. 
Thank you for this comment. We shortened the ‘Introduction’ part of our paper, as it was 
recommended. 
 
-     In the results section, authors state: "Finally, we used the data from ten trials…". Indeed, 
they included 8 RCTs, and two observational studies, so the word "trials" should be replaced 
with "studies". This mistake is repeated in other parts of the manuscript. 
Thank you for this comment. We carefully read through and corrected our manuscript 
accordingly. We used the word ‘studies’ instead of ‘trials’ throughout the text.  
 
We would like to thank the reviewers again for their excellent comments, which have 
significantly improved the quality of our manuscript. 
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Abstract 
Background: Despite the high rate of postoperative recurrence (POR) in Crohn’s disease 
(CD), there is no widely accepted consensus on its prevention. 
Aim: To compare the efficacy of biological and conventional therapies in preventing POR of 
CD. 
Methods: We searched four electronic databases up to April 2019 for articles that examined 
the efficacy of different preventive therapies against POR. Our PICO was: (P) adults with CD 
who underwent intestinal resection, (I) biological agents, (C) conventional therapies or a 
placebo, and (O) clinical, endoscopic, and histological POR.  
Results: Anti-TNFα agents were significantly better in preventing clinical, endoscopic, severe 
endoscopic and histological POR compared to conventional therapies (OR: 0.508, 95% CI: 
0.309–0.834, P = 0.007; OR: 0.312, 95% CI: 0.199–0.380, P < 0.001; OR: 0.195, 95% CI: 
0.107–0.356, P < 0.001; and OR: 0.255, 95% CI: 0.106–0.611, P = 0.002, respectively), as 
well as in the subgroup of nonselected CD patients (OR: 0.324, 95% CI: 0.158–0.664, P = 
0.002; OR: 0.225, 95% CI: 0.124–0.409, P < 0.001; and OR: 0.248, 95% CI: 0.070–0.877, P 
= 0.031, respectively). Infliximab and adalimumab proved to be equally effective in 
preventing endoscopic POR. 
Conclusion: Anti-TNFα agents are more effective in preventing clinical, endoscopic and 
histological POR than conventional therapies, even in nonselected CD patients.  
Keywords: Crohn’s disease; postoperative recurrence; preventive treatment; anti-TNFα; 
infliximab; adalimumab  
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Introduction 
Crohn’s disease (CD) is one of the main types of inflammatory bowel disease causing 
transmural inflammation at any part of the gastrointestinal tract. Up to 75% of patients with 
CD require surgery for disease complications, and a high percentage of CD patients relapse 
after surgery [1]. Due to postoperative medically refractory disease or complications, around 
50–60% of patients require repeat surgical interventions [2]. Early recognition of 
postoperative recurrence (POR), defined by a continuum of histological, endoscopic and 
clinical recurrence, is therefore crucial in the management of patients to avoid bowel 
destruction [3]. 
Several different activity indices are used to grade clinical POR, such as the Crohn’s 
Disease Activity Index (CDAI) [4], the Clinical Recurrence Grading Scale (CRGS) developed 
by Hanauer [5], the Harvey–Bradshaw Index (HBI) [6] and the Index of Inflammatory Bowel 
Disease (IOIBD) [7]. However, these activity indices have not proven adaptable for 
postoperative conditions, since nearly 70–80% of CD patients develop endoscopic recurrence 
without any sign of clinical recurrence within the first postoperative year [8]. Therefore, 
ileocolonoscopy is recommended as the gold standard method for diagnosing endoscopic 
lesions within the first year after surgery, using the Rutgeerts’ scoring system [9]. Histologic 
recurrence is based on a histologic activity score and the presence of polymorphonuclear cells 
[10]. 
To address a major clinical challenge, there is a current need for recommendations on 
the best choice of preventive treatment for CD patients after bowel resection. In clinical 
practice, patients with ≥2 established risk factors (e.g., active smoking, previous resections, or 
penetrating or perianal disease) should be considered as being at high risk for POR [11]. In 
this high-risk patient population, the initiation of prophylactic medical treatment is 
recommended to maintain surgically induced remission [9, 12].  
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Many studies have been conducted over the past years to evaluate the efficacy of 
different medications in preventing POR. Nitroimidazole antibiotics may reduce POR 
following ileocolic resection, though frequent side-effects limit their use [13, 14]. Results 
with 5-aminosalicylates (mesalamine; MSN) are contradictory.
 
Thiopurines such as 
azathioprine (AZA) and 6-mercaptopurine (6-MP) are obviously superior to placebos (PLAC) 
in preventing both clinical and endoscopic POR [15]. In contrast, AZA failed to demonstrate 
its superiority over 5-ASA preparations in a previous Cochrane review [16]. 
 
Lately, the use of anti-tumour necrosis factor alpha agents (anti-TNFα; infliximab [IFX] 
and adalimumab [ADA]) for preventing POR has come into focus. A subanalysis of the 
POCER study confirmed the superiority of ADA over thiopurines for preventing endoscopic 
POR in high-risk patients [17]. On the other hand, ADA failed to demonstrate better efficacy 
than AZA for preventing POR in a nonselected population (APPRECIA study) [18]. The 
PREVENT authors concluded that IFX prevents endoscopic POR but not clinical POR [19].
  
Previous head-to-head and network meta-analyses from 2014 and 2015 found that anti-
TNFα agents are the most potent in preventing clinical and endoscopic POR [20-23]. Since 
then, new studies have been released and novel biological agents in the treatment of IBD have 
been introduced (e.g., vedolizumab (VDZ) and ustekinumab). We therefore aimed to provide 
an update summarizing the currently available evidence on the efficacy of biological agents in 
POR prevention. None of the previously published meta-analyses examined which patient 
population could benefit most from the introduction of preventive anti-TNFα treatment, 
therefore we also aimed to answer this question.  
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Material and Methods 
This meta-analysis was reported in accordance with the Preferred Reporting Items for 
Systematic Reviews and Meta-Analyses (PRISMA) statement (Supplementary Table 1)[24]. 
The protocol was registered in the International Prospective Register of Systematic Reviews 
(PROSPERO) and approved under identification number CRD42017083679. 
 
Literature search 
We conducted a computerized search up to 12 April 2019 in the following four electronic 
databases: PubMed (http://www.ncbi.nlm.nih.gov/pubmed), EMBASE 
(https://www.embase.com), the Central Cochrane Register of Controlled Trials (CENTRAL) 
(http://www.cochranelibrary.com) and Web of Science (www.webofknowledge.com). The 
filter ‘humans’ was applied. 
Based on the PICO format, we examined the population (P) of adults with CD after 
intestinal resection. The outcomes (O) examined consisted of clinical, endoscopic, severe 
endoscopic and histological POR. Biologics (ADA, IFX, VDZ, golimumab, certolizumab and 
ustekinumab) represented the intervention (I), and the comparators (C) were different 
conventional, non-biological treatment options (AZA, 6-MP, MSN or PLAC). Preventive 
therapy was initiated within 2–6 weeks (defined as early initiation) after surgery in all of the 
studies. 
A systematic literature search was performed with a combination of medical subject 
headings (MeSH) and free text terms: Crohn AND (adalimumab OR infliximab OR 
certolizumab OR golimumab OR vedolizumab OR ustekinumab OR ”anti-tumor necosis 
factor” OR ”monoclonal antibody” OR biologic) AND (postop* OR surgery OR surgical OR 
postsurg* OR operation OR resection) AND (recur* OR ”flare-up” OR relaps* OR 
remission) AND (prevent* OR prophyla*). 
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Study selection 
After the database search, one author (AE) removed the overlapping records and duplicates 
using reference management software (EndNote X8, Clarivate Analytics, Philadelphia, PA, 
USA). First, the list of potentially eligible records (by title and abstract) were screened 
independently by two authors (AE and PS) to capture all relevant records. Two authors (AE 
and PS) screened the full texts of the remaining articles for eligibility. Consensus involving a 
third party (PH) resolved discrepancies when necessary. 
 Studies evaluating human CD patients (aged ≥18 years) who underwent ileocecal, 
ileocolic or colonic resection due to perforation, stricture and penetrating complications 
related to intra-abdominal abscess formation, drug therapy failure, disease activity or internal 
fistula formation were eligible for inclusion. English-language papers were selected, where 
therapy was initiated with the purpose of POR prevention within 2–7 weeks after surgery. 
Studies comparing the efficacy of biologics and any conventional, non-biological treatment 
options were included in our meta-analysis. 
 We excluded review articles, case reports and scientific studies only published in 
abstract form, studies evaluating treatment administered with an indication other than 
prevention of POR and uncontrolled studies. 
 
Data extraction 
The following data were extracted from each included study (Tables 1 and Supplementary 
Table 2): first author, year of publication, study type (prospective/retrospective; 
randomized/non-randomized), number of participating centres, length of the follow-up, drug 
regimen and number of patients in each study arm. As for the outcomes, the number of 
patients with clinical, endoscopic, severe endoscopic and histological POR were collected in 
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each study arm. The baseline characteristics (Table 1) of the examined population were 
collected, including gender distribution, age, disease duration and main risk factors (smoking, 
penetrating disease, perianal location and number of previous resections). Data on the 
Montreal classification at the time of enrolment was gathered as well. 
The endpoints of our meta-analysis were clinical, endoscopic, severe endoscopic and 
histological POR. Studies used different types of indices to define clinical recurrence, such as 
CDAI [10, 17-19, 25, 26], HBI [27-29], IOIBD [30] and Hanauer scores [31]. Endoscopic 
POR and severe endoscopic POR were defined with a Rutgeerts score of ≥i2 and ≥i3, 
respectively. Histological recurrence was determined by an expert pathologist [29] or by using 
the modified histology scoring system of D’Haens (an overall score greater than 6 with at 
least a grade 1 polymorphonuclear score) [10, 28]. 
Firstly, anti-TNFα agents (ADA or IFX) as interventions were compared to different 
conventional, non-biological prophylactic options (AZA, 6-MP, MSN or PLAC). Next, 
comparisons of anti-TNFα agents (ADA or IFX) versus thiopurines alone (AZA or 6-MP) 
were examined separately. Thereafter, a head-to-head comparison of ADA and IFX was 
performed. 
Subgroup analyses were carried out to investigate the differences deriving from patient 
selection. In our meta-analysis, patients were considered to have a high risk of POR if they 
were exposed to >1 of the following risk factors: active smoking, young age at diagnosis, 
penetrating or perianal disease at diagnosis, >1 resections and a resection within three years. 
As a comparator, a group of nonselected patients without risk factors for POR was used.  
For safety analysis, adverse events (AE) and severe adverse events (SAE) were 
categorized in accordance with the definitions of the International Conference on 
Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human use 
- Good Clinical Practice (ICH-GCP) consensus guidelines [32]. 
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Risk of bias 
The two investigators (AE and PS) first assessed the methodological quality of selected 
studies independently, and then disagreements were resolved. If consensus could not be 
reached, the authors asked for a second opinion from a third investigator (PH). The Cochrane 
Risk of Bias Tool was used [33] for a risk of bias assessment of the included RCTs. Seven 
items in this tool were rated as having a low risk of bias (marked with a green plus sign), a 
high risk of bias (marked with a red minus sign) and an unclear risk of bias (marked with a 
yellow question mark). 
A topic-tailored form of the Newcastle–Ottawa Scale (NOS) was used [34] to assess 
the risk of bias of the included observational studies. We evaluated the included studies with 
eight items from three domains (selection, comparability and outcome). One star was assigned 
to each item, except for comparability, for which a maximum of two stars was possible. The 
highest possible score was nine. Each item was classified as having a low risk of bias (marked 
as a green plus sign equalling 1 star) or a high or unclear risk of bias (marked as a red minus 
mark equalling 0 star), corresponding to our specified definitions. 
 
Statistical analysis 
All meta-analytic calculations were performed with Comprehensive MetaAnalysis software 
Version 3 (Biostat, Inc., Englewood, NJ, USA). Since binary outcomes were used, odds ratios 
(OR) with a 95% confidence interval (CI) were calculated, using the random-effects model 
developed by DerSimonian and Laird [35]. Forest plots were used to display the results of the 
statistical analysis. All analyses were two-tailed and P < 0.05 was considered as significant. 
Heterogeneity was assessed using Cochrane’s Q and the I2 statistics. In the case of the 
Q statistic, Q exceeds the upper-tail critical value of chi-square with k-1 degree of freedom. I
2
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represents the percentage of effect size heterogeneity, which cannot be explained by random 
chance. According to the Cochrane Handbook, heterogeneity could be interpreted as moderate 
between 30 and 60%, as substantial between 50 and 90% and as considerable above 75% [33]. 
Meta-regression was used to detect the effect of length of follow-up on the effect sizes 
if we had at least 10 publications reporting the same outcomes. Our null-hypothesis was that 
the coefficients are zero. The results were described with regression coefficients, 95% CI-s, 
probability-values (P) and the explained variances of the models (R
2
 analogs). 
Publication bias was evaluated by visual inspection of the funnel plot due to the small 
number of articles included in our meta-analysis.  
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Results 
 
Study selection 
Our comprehensive literature search identified a total of 1,143 records (shown on the 
PRISMA flow chart; Supplementary Figure 1) in four electronic databases (143 articles in 
PubMed, 704 in EMBASE, 83 in CENTRAL and 213 in Web of Science). After the removal 
of duplicates, 722 records remained, of which 694 were excluded by title and abstract. 
According to our inclusion and exclusion criteria, 23 potentially eligible articles were 
considered for inclusion based on full texts. Out of these studies, nine were excluded due to 
the following reasons: two studies 
 
did not meet the criteria on the outcome measures [36, 37], 
three studies were previously published systematic reviews or meta-analyses [38-40], one 
study did not report the outcomes by treatment [41] and three studies had no control arm [42-
44]. Finally, the 14 remaining studies fulfilled all inclusion criteria and were included in the 
meta-analysis [10, 17-19, 25-31, 45-47]. 
 
Characteristics of the studies included 
The main characteristics of the included studies are listed in Supplementary Table 2. The 
studies were published from 2007 to 2018, and the follow-up period in the studies ranged 
from six to 36 months. Finally, we used the data from 14 studies, including a total of 1,224 
CD patients (573 patients received biologics, and 620 patients received non-biological drugs). 
Ten articles were randomized controlled trials (RCT) [10, 17-19, 25-28, 30, 47], four [17, 18, 
25, 47] and six studies [10, 19, 26, 28, 30, 31] compared the efficacy of ADA and IFX to non-
biological comparators (AZA, MSN and PLAC), respectively. Two studies compared anti-
TNFα agents to conventional, non-biological therapies [29, 46]. Two papers [27, 45] reported 
on the head-to-head efficacy of ADA and IFX in preventing POR: one of them was a 
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retrospective study [45], the another one was an RCT [27]. Two articles only included high-
risk patients in their analysis [17, 28], and eight ones involved nonselected CD patients [10, 
18, 19, 25, 26, 29-31].  
Only one study by Yamada compared the efficacy of VDZ and conventional therapies 
with respect to the prevention of POR [29]. Due to the low number of VDZ patients and to 
that the same group (AZA) was compared to both VDZ and anti-TNFα patients, we were 
unable to set up a VDZ subgroup in our meta-analysis.  
 
Comparison of preventive anti-TNFα versus conventional therapy for POR 
Twelve studies assessed POR comparing anti-TNFα therapy to different, non-biological 
prophylactic options [10, 17-19, 25, 26, 28-31, 46, 47]
 
(Figures 1, 2 and 3). There was a 
significantly lower rate of clinical, endoscopic, severe endoscopic and histological POR in the 
anti-TNFα group compared to the non-biological treatment group (OR: 0.508, 95% CI: 
0.309–0.834, P = 0.007; OR: 0.312, 95% CI: 0.199–0.489, P < 0.001; OR: 0.195, 95% CI: 
0.195–0.356, P < 0.001; and OR: 0.255, 95 CI: 0.106–0.611, P = 0.002, respectively). 
Substantial heterogeneity was detected only in the case of histological recurrence (I2 = 63.2%, 
P = 0.066), while the analysis showed moderate heterogeneity in the case of clinical, 
endoscopic and severe endoscopic recurrence (I
2 
= 38.4%, P = 0.102; I
2 
= 38.0%, P = 0.088; 
I
2 
= 35.3%, P = 0.159 and, respectively) (Supplementary Table 3). 
The superiority of anti-TNFα treatment over thiopurines could only be demonstrated 
in the case of endoscopic POR (OR: 0.392, 95% CI: 0.241–0.639; P < 0.001) (Supplementary 
Figures 2, 3 and 4). 
Twelve studies were eligible for meta-regression. No statistically significant linear 
correlation was observed between clinical and endoscopic POR and time during the examined 
follow-up (P = 0.154 and P = 0.411, respectively) (Supplementary Figures 5 and 6). 
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Comparison of infliximab and adalimumab for the prevention of endoscopic POR 
An evaluation of the homogeneous data (I
2 
= 0.0%; P = 0.640) from the two head-to-head 
comparison studies [27, 45] found no significant difference between ADA and IFX with 
regard to endoscopic POR rates (OR: 0.799, 95% CI: 0.329–1.940; P = 0.620) (Figure 4). 
 
Efficacy of prophylactic anti-TNFα agents in nonselected CD patients 
Only two studies assessed the efficacy of anti-TNFα agents with regard to POR in high-risk 
patients [17, 28], while eight studies 
 
did not separate patients into risk groups (i.e., they did 
not include a selected patient group) [10, 18, 19, 25, 26, 29-31] (Figures 5 a, 5b and 5c). Anti-
TNFα agents showed a significantly better efficacy in preventing clinical, endoscopic and 
severe endoscopic POR in a nonselected CD population (OR: 0.324, 95% CI: 0.158–0.664, P 
= 0.002; OR: 0.225, 95% CI: 0.124–0.409, P < 0.001; and OR: 0.248, 95% CI: 0.070–0.877, 
P = 0.031, respectively). The overall heterogeneity was the highest in the analysis of severe 
endoscopic POR (I
2 
= 55.3%; P = 0.062) (Supplementary Table 3).  
 
Safety analysis 
Six of the fourteen studies reported the rate of adverse events (AEs) of postoperative 
preventive treatments [10, 17-19, 25, 28], while three studies reported the rate of SAEs [17-
19]. No significant difference was observed in AE or SAE rates between the anti-TNFα and 
the conventional treatment groups (OR: 0.86, 95% CI: 0.457-1.617, P = 0.639; and OR: 
1.018, 95% CI: 0.641-1.617, P = 0.94, respectively) (Supplementary Figure 7a and 7b). 
 
Risk of bias assessment 
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Risk of bias assessments of the included studies are shown in Supplementary Figure 8. In 
RTCs, random sequence generation was described in sufficient detail in only 40% and 
allocation concealment in only 30% of the articles. Four studies were open-label studies; they 
therefore carried a high risk of bias due to lack of blinding among participants and personnel. 
In four studies, the assessment of outcomes was unblinded or not described accurately. All of 
the studies were judged as being low risk with regard to the item of incomplete outcome, 
excepting the study of Scapa, which was only published in abstract form. All of the studies 
were judged as being free from other potential sources of bias, excepting the study of Scapa 
(unclear risk of bias) and the study of Fukushima (high risk of bias). As for selective 
reporting, we failed to identify half of the studies in trial protocol databases; they were 
therefore considered to have an unclear risk of bias in this regard. 
All of the included observational studies were considered low-risk studies with regard 
to each item, except for assessment of outcome. From this point of view, they were both 
assigned zero stars because none of them detailed blinding for the outcome assessment 
(whether endoscopic operators performing control endoscopies were blinded or not). In the 
study of Auzolle, the comparability of the cohorts of patients could not be judged based on the 
article content. According to our assessment, the included observational studies achieved six 
to eight points out of a maximum of nine. 
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Discussion 
Most of the patients with CD require surgery during their lifetime. Within one year, 80% of 
operated patients develop endoscopic POR. However, there is no widely accepted consensus 
on the prevention of POR, though the issue has been approached through multiple meta-
analyses and a Cochrane review in recent years. 
In our meta-analysis, we used the most up-to-date data from 14 clinical studies, of 
which most were RCTs. Most of the included studies compared the efficacy of anti-TNFα 
agents to non-biological comparators in preventing clinical, endoscopic, severe endoscopic 
and histological POR. The minority compared the efficacy of ADA and IFX. We made an 
effort to synthesize all the possible comparisons in our meta-analysis. 
Firstly, we evaluated the efficacy of anti-TNFα agents compared to non-biological 
comparators. Based on our results, anti-TNFα agents were significantly more effective in 
preventing clinical, endoscopic, severe endoscopic and histological POR. Our findings 
confirm results from previous meta-analyses [20-22].
 
As part of our comparison, we analysed 
the efficacy of anti-TNFα agents compared to the thiopurine-treated group. Anti-TNFα agents 
proved to be better in all kinds of analysed POR prevention, but their superiority over 
thiopurines could only be detected in the case of endoscopic POR. 
Secondly, we performed a direct, head-to-head comparison between ADA and IFX in 
preventing endoscopic POR. We found that the efficacy of these two anti-TNFα agents is 
nearly the same, thus confirming previously performed indirect comparisons [21, 48]. 
Thirdly, uniquely in the literature so far, we aimed to identify groups of patients who 
will benefit most from a preventive anti-TNFα treatment after resection. We therefore 
compared the anti-TNFα agents to controls in the high-risk and nonselected CD patient 
subgroups. The analysis indicated that nonselected patients enjoy the benefits of preventive 
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anti-TNFα treatment with respect to clinical, endoscopic and severe endoscopic POR as well, 
independently from risk stratification. 
Our meta-analysis has several strengths worth highlighting. A high number (1,124) of 
operated CD patients were enrolled in the analyses, and most of the included studies were 
RCTs. This is the first meta-analysis involving subgroup analyses on patient selection upon 
risk stratification. A head-to-head comparison between IFX and ADA was also possible, 
which confirmed previous indirect comparisons. Today, mucosal healing is considered as one 
of the hardest endpoints in predicting long-term clinical success in IBD [49]. Closely related 
to this, we examined the efficacy of anti-TNFα treatment compared to conventional therapies 
with respect to the prevention of histological POR.  
However, we are aware that our findings suffer from several limitations. First, we 
could not investigate the effect of co-treatments used in the different treatment arms. Second, 
the follow-up period in the included studies ranged between six and 36 months, although most 
reported the results at one year. Finally, we could not evaluate the effect of new biologics 
(e.g., VDZ and ustekinumab) on POR prevention, since there have been just very few results 
published on this field. 
 In summary, the results from our meta-analysis confirm that early initiated 
postoperative anti-TNFα treatment is currently the most effective therapeutic choice in 
preventing the continuum of histological, endoscopic, and clinical POR without increasing the 
frequency of AEs. Our findings suggest that it is unnecessary to select patients after intestinal 
resection based on risk factors since even nonselected populations can benefit from early 
initiated prophylactic anti-TNFα therapy postoperatively. Both IFX and ADA are equally 
effective in preventing endoscopic POR. Further large RCTs are needed to confirm and 
strengthen our results.  
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Abstract 
Background: Despite the high rate of postoperative recurrence (POR) in Crohn’s disease 
(CD), there is no widely accepted consensus on its prevention. 
Aim: To compare the efficacy of biological and conventional therapies in preventing POR of 
CD. 
Methods: We searched four electronic databases up to April 2019 for articles that examined 
the efficacy of different preventive therapies against POR. Our PICO was: (P) adults with CD 
who underwent intestinal resection, (I) biological agents, (C) conventional therapies or a 
placebo, and (O) clinical, endoscopic, and histological POR.  
Results: Anti-TNFα agents were significantly better in preventing clinical, endoscopic, severe 
endoscopic and histological POR compared to conventional therapies (OR: 0.508, 95% CI: 
0.309–0.834, P = 0.007; OR: 0.312, 95% CI: 0.199–0.380, P < 0.001; OR: 0.195, 95% CI: 
0.107–0.356, P < 0.001; and OR: 0.255, 95% CI: 0.106–0.611, P = 0.002, respectively), as 
well as in the subgroup of nonselected CD patients (OR: 0.324, 95% CI: 0.158–0.664, P = 
0.002; OR: 0.225, 95% CI: 0.124–0.409, P < 0.001; and OR: 0.248, 95% CI: 0.070–0.877, P 
= 0.031, respectively). Infliximab and adalimumab proved to be equally effective in 
preventing endoscopic POR. 
Conclusion: Anti-TNFα agents are more effective in preventing clinical, endoscopic and 
histological POR than conventional therapies, even in nonselected CD patients.  
Keywords: Crohn’s disease; postoperative recurrence; preventive treatment; anti-TNFα; 
infliximab; adalimumab  
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Introduction 
Crohn’s disease (CD) is one of the main types of inflammatory bowel disease causing 
transmural inflammation at any part of the gastrointestinal tract. Up to 75% of patients with 
CD require surgery for disease complications, and a high percentage of CD patients relapse 
after surgery [1]. Due to postoperative medically refractory disease or complications, around 
50–60% of patients require repeat surgical interventions [2]. Early recognition of 
postoperative recurrence (POR), defined by a continuum of histological, endoscopic and 
clinical recurrence, is therefore crucial in the management of patients to avoid bowel 
destruction [3]. 
Several different activity indices are used to grade clinical POR, such as the Crohn’s 
Disease Activity Index (CDAI) [4], the Clinical Recurrence Grading Scale (CRGS) developed 
by Hanauer [5], the Harvey–Bradshaw Index (HBI) [6] and the Index of Inflammatory Bowel 
Disease (IOIBD) [7]. However, these activity indices have not proven adaptable for 
postoperative conditions, since nearly 70–80% of CD patients develop endoscopic recurrence 
without any sign of clinical recurrence within the first postoperative year [8]. Therefore, 
ileocolonoscopy is recommended as the gold standard method for diagnosing endoscopic 
lesions within the first year after surgery, using the Rutgeerts’ scoring system [9]. Histologic 
recurrence is based on a histologic activity score and the presence of polymorphonuclear cells 
[10]. 
To address a major clinical challenge, there is a current need for recommendations on 
the best choice of preventive treatment for CD patients after bowel resection. In clinical 
practice, patients with ≥2 established risk factors (e.g., active smoking, previous resections, or 
penetrating or perianal disease) should be considered as being at high risk for POR [11]. In 
this high-risk patient population, the initiation of prophylactic medical treatment is 
recommended to maintain surgically induced remission [9, 12].  
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Many studies have been conducted over the past years to evaluate the efficacy of 
different medications in preventing POR. Nitroimidazole antibiotics may reduce POR 
following ileocolic resection, though frequent side-effects limit their use [13, 14]. Results 
with 5-aminosalicylates (mesalamine; MSN) are contradictory.
 
Thiopurines such as 
azathioprine (AZA) and 6-mercaptopurine (6-MP) are obviously superior to placebos (PLAC) 
in preventing both clinical and endoscopic POR [15]. In contrast, AZA failed to demonstrate 
its superiority over 5-ASA preparations in a previous Cochrane review [16]. 
 
Lately, the use of anti-tumour necrosis factor alpha agents (anti-TNFα; infliximab [IFX] 
and adalimumab [ADA]) for preventing POR has come into focus. A subanalysis of the 
POCER study confirmed the superiority of ADA over thiopurines for preventing endoscopic 
POR in high-risk patients [17]. On the other hand, ADA failed to demonstrate better efficacy 
than AZA for preventing POR in a nonselected population (APPRECIA study) [18]. The 
PREVENT authors concluded that IFX prevents endoscopic POR but not clinical POR [19].
  
Previous head-to-head and network meta-analyses from 2014 and 2015 found that anti-
TNFα agents are the most potent in preventing clinical and endoscopic POR [20-23]. Since 
then, new studies have been released and novel biological agents in the treatment of IBD have 
been introduced (e.g., vedolizumab (VDZ) and ustekinumab). We therefore aimed to provide 
an update summarizing the currently available evidence on the efficacy of biological agents in 
POR prevention. None of the previously published meta-analyses examined which patient 
population could benefit most from the introduction of preventive anti-TNFα treatment, 
therefore we also aimed to answer this question.  
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Material and Methods 
This meta-analysis was reported in accordance with the Preferred Reporting Items for 
Systematic Reviews and Meta-Analyses (PRISMA) statement (Supplementary Table 1)[24]. 
The protocol was registered in the International Prospective Register of Systematic Reviews 
(PROSPERO) and approved under identification number CRD42017083679. 
 
Literature search 
We conducted a computerized search up to 12 April 2019 in the following four electronic 
databases: PubMed (http://www.ncbi.nlm.nih.gov/pubmed), EMBASE 
(https://www.embase.com), the Central Cochrane Register of Controlled Trials (CENTRAL) 
(http://www.cochranelibrary.com) and Web of Science (www.webofknowledge.com). The 
filter ‘humans’ was applied. 
Based on the PICO format, we examined the population (P) of adults with CD after 
intestinal resection. The outcomes (O) examined consisted of clinical, endoscopic, severe 
endoscopic and histological POR. Biologics (ADA, IFX, VDZ, golimumab, certolizumab and 
ustekinumab) represented the intervention (I), and the comparators (C) were different 
conventional, non-biological treatment options (AZA, 6-MP, MSN or PLAC). Preventive 
therapy was initiated within 2–6 weeks (defined as early initiation) after surgery in all of the 
studies. 
A systematic literature search was performed with a combination of medical subject 
headings (MeSH) and free text terms: Crohn AND (adalimumab OR infliximab OR 
certolizumab OR golimumab OR vedolizumab OR ustekinumab OR ”anti-tumor necosis 
factor” OR ”monoclonal antibody” OR biologic) AND (postop* OR surgery OR surgical OR 
postsurg* OR operation OR resection) AND (recur* OR ”flare-up” OR relaps* OR 
remission) AND (prevent* OR prophyla*). 
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Study selection 
After the database search, one author (AE) removed the overlapping records and duplicates 
using reference management software (EndNote X8, Clarivate Analytics, Philadelphia, PA, 
USA). First, the list of potentially eligible records (by title and abstract) were screened 
independently by two authors (AE and PS) to capture all relevant records. Two authors (AE 
and PS) screened the full texts of the remaining articles for eligibility. Consensus involving a 
third party (PH) resolved discrepancies when necessary. 
 Studies evaluating human CD patients (aged ≥18 years) who underwent ileocecal, 
ileocolic or colonic resection due to perforation, stricture and penetrating complications 
related to intra-abdominal abscess formation, drug therapy failure, disease activity or internal 
fistula formation were eligible for inclusion. English-language papers were selected, where 
therapy was initiated with the purpose of POR prevention within 2–7 weeks after surgery. 
Studies comparing the efficacy of biologics and any conventional, non-biological treatment 
options were included in our meta-analysis. 
 We excluded review articles, case reports and scientific studies only published in 
abstract form, studies evaluating treatment administered with an indication other than 
prevention of POR and uncontrolled studies. 
 
Data extraction 
The following data were extracted from each included study (Tables 1 and Supplementary 
Table 2): first author, year of publication, study type (prospective/retrospective; 
randomized/non-randomized), number of participating centres, length of the follow-up, drug 
regimen and number of patients in each study arm. As for the outcomes, the number of 
patients with clinical, endoscopic, severe endoscopic and histological POR were collected in 
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each study arm. The baseline characteristics (Table 1) of the examined population were 
collected, including gender distribution, age, disease duration and main risk factors (smoking, 
penetrating disease, perianal location and number of previous resections). Data on the 
Montreal classification at the time of enrolment was gathered as well. 
The endpoints of our meta-analysis were clinical, endoscopic, severe endoscopic and 
histological POR. Studies used different types of indices to define clinical recurrence, such as 
CDAI [10, 17-19, 25, 26], HBI [27-29], IOIBD [30] and Hanauer scores [31]. Endoscopic 
POR and severe endoscopic POR were defined with a Rutgeerts score of ≥i2 and ≥i3, 
respectively. Histological recurrence was determined by an expert pathologist [29] or by using 
the modified histology scoring system of D’Haens (an overall score greater than 6 with at 
least a grade 1 polymorphonuclear score) [10, 28]. 
Firstly, anti-TNFα agents (ADA or IFX) as interventions were compared to different 
conventional, non-biological prophylactic options (AZA, 6-MP, MSN or PLAC). Next, 
comparisons of anti-TNFα agents (ADA or IFX) versus thiopurines alone (AZA or 6-MP) 
were examined separately. Thereafter, a head-to-head comparison of ADA and IFX was 
performed. 
Subgroup analyses were carried out to investigate the differences deriving from patient 
selection. In our meta-analysis, patients were considered to have a high risk of POR if they 
were exposed to >1 of the following risk factors: active smoking, young age at diagnosis, 
penetrating or perianal disease at diagnosis, >1 resections and a resection within three years. 
As a comparator, a group of nonselected patients without risk factors for POR was used.  
For safety analysis, adverse events (AE) and severe adverse events (SAE) were 
categorized in accordance with the definitions of the International Conference on 
Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human use 
- Good Clinical Practice (ICH-GCP) consensus guidelines [32]. 
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Risk of bias 
The two investigators (AE and PS) first assessed the methodological quality of selected 
studies independently, and then disagreements were resolved. If consensus could not be 
reached, the authors asked for a second opinion from a third investigator (PH). The Cochrane 
Risk of Bias Tool was used [33] for a risk of bias assessment of the included RCTs. Seven 
items in this tool were rated as having a low risk of bias (marked with a green plus sign), a 
high risk of bias (marked with a red minus sign) and an unclear risk of bias (marked with a 
yellow question mark). 
A topic-tailored form of the Newcastle–Ottawa Scale (NOS) was used [34] to assess 
the risk of bias of the included observational studies. We evaluated the included studies with 
eight items from three domains (selection, comparability and outcome). One star was assigned 
to each item, except for comparability, for which a maximum of two stars was possible. The 
highest possible score was nine. Each item was classified as having a low risk of bias (marked 
as a green plus sign equalling 1 star) or a high or unclear risk of bias (marked as a red minus 
mark equalling 0 star), corresponding to our specified definitions. 
 
Statistical analysis 
All meta-analytic calculations were performed with Comprehensive MetaAnalysis software 
Version 3 (Biostat, Inc., Englewood, NJ, USA). Since binary outcomes were used, odds ratios 
(OR) with a 95% confidence interval (CI) were calculated, using the random-effects model 
developed by DerSimonian and Laird [35]. Forest plots were used to display the results of the 
statistical analysis. All analyses were two-tailed and P < 0.05 was considered as significant. 
Heterogeneity was assessed using Cochrane’s Q and the I2 statistics. In the case of the 
Q statistic, Q exceeds the upper-tail critical value of chi-square with k-1 degree of freedom. I
2
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represents the percentage of effect size heterogeneity, which cannot be explained by random 
chance. According to the Cochrane Handbook, heterogeneity could be interpreted as moderate 
between 30 and 60%, as substantial between 50 and 90% and as considerable above 75% [33]. 
Meta-regression was used to detect the effect of length of follow-up on the effect sizes 
if we had at least 10 publications reporting the same outcomes. Our null-hypothesis was that 
the coefficients are zero. The results were described with regression coefficients, 95% CI-s, 
probability-values (P) and the explained variances of the models (R
2
 analogs). 
Publication bias was evaluated by visual inspection of the funnel plot due to the small 
number of articles included in our meta-analysis.  
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Results 
 
Study selection 
Our comprehensive literature search identified a total of 1,143 records (shown on the 
PRISMA flow chart; Supplementary Figure 1) in four electronic databases (143 articles in 
PubMed, 704 in EMBASE, 83 in CENTRAL and 213 in Web of Science). After the removal 
of duplicates, 722 records remained, of which 694 were excluded by title and abstract. 
According to our inclusion and exclusion criteria, 23 potentially eligible articles were 
considered for inclusion based on full texts. Out of these studies, nine were excluded due to 
the following reasons: two studies 
 
did not meet the criteria on the outcome measures [36, 37], 
three studies were previously published systematic reviews or meta-analyses [38-40], one 
study did not report the outcomes by treatment [41] and three studies had no control arm [42-
44]. Finally, the 14 remaining studies fulfilled all inclusion criteria and were included in the 
meta-analysis [10, 17-19, 25-31, 45-47]. 
 
Characteristics of the studies included 
The main characteristics of the included studies are listed in Supplementary Table 2. The 
studies were published from 2007 to 2018, and the follow-up period in the studies ranged 
from six to 36 months. Finally, we used the data from 14 studies, including a total of 1,224 
CD patients (573 patients received biologics, and 620 patients received non-biological drugs). 
Ten articles were randomized controlled trials (RCT) [10, 17-19, 25-28, 30, 47], four [17, 18, 
25, 47] and six studies [10, 19, 26, 28, 30, 31] compared the efficacy of ADA and IFX to non-
biological comparators (AZA, MSN and PLAC), respectively. Two studies compared anti-
TNFα agents to conventional, non-biological therapies [29, 46]. Two papers [27, 45] reported 
on the head-to-head efficacy of ADA and IFX in preventing POR: one of them was a 
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retrospective study [45], the another one was an RCT [27]. Two articles only included high-
risk patients in their analysis [17, 28], and eight ones involved nonselected CD patients [10, 
18, 19, 25, 26, 29-31].  
Only one study by Yamada compared the efficacy of VDZ and conventional therapies 
with respect to the prevention of POR [29]. Due to the low number of VDZ patients and to 
that the same group (AZA) was compared to both VDZ and anti-TNFα patients, we were 
unable to set up a VDZ subgroup in our meta-analysis.  
 
Comparison of preventive anti-TNFα versus conventional therapy for POR 
Twelve studies assessed POR comparing anti-TNFα therapy to different, non-biological 
prophylactic options [10, 17-19, 25, 26, 28-31, 46, 47]
 
(Figures 1, 2 and 3). There was a 
significantly lower rate of clinical, endoscopic, severe endoscopic and histological POR in the 
anti-TNFα group compared to the non-biological treatment group (OR: 0.508, 95% CI: 
0.309–0.834, P = 0.007; OR: 0.312, 95% CI: 0.199–0.489, P < 0.001; OR: 0.195, 95% CI: 
0.195–0.356, P < 0.001; and OR: 0.255, 95 CI: 0.106–0.611, P = 0.002, respectively). 
Substantial heterogeneity was detected only in the case of histological recurrence (I2 = 63.2%, 
P = 0.066), while the analysis showed moderate heterogeneity in the case of clinical, 
endoscopic and severe endoscopic recurrence (I
2 
= 38.4%, P = 0.102; I
2 
= 38.0%, P = 0.088; 
I
2 
= 35.3%, P = 0.159 and, respectively) (Supplementary Table 3). 
The superiority of anti-TNFα treatment over thiopurines could only be demonstrated 
in the case of endoscopic POR (OR: 0.392, 95% CI: 0.241–0.639; P < 0.001) (Supplementary 
Figures 2, 3 and 4). 
Twelve studies were eligible for meta-regression. No statistically significant linear 
correlation was observed between clinical and endoscopic POR and time during the examined 
follow-up (P = 0.154 and P = 0.411, respectively) (Supplementary Figures 5 and 6). 
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Comparison of infliximab and adalimumab for the prevention of endoscopic POR 
An evaluation of the homogeneous data (I
2 
= 0.0%; P = 0.640) from the two head-to-head 
comparison studies [27, 45] found no significant difference between ADA and IFX with 
regard to endoscopic POR rates (OR: 0.799, 95% CI: 0.329–1.940; P = 0.620) (Figure 4). 
 
Efficacy of prophylactic anti-TNFα agents in nonselected CD patients 
Only two studies assessed the efficacy of anti-TNFα agents with regard to POR in high-risk 
patients [17, 28], while eight studies 
 
did not separate patients into risk groups (i.e., they did 
not include a selected patient group) [10, 18, 19, 25, 26, 29-31] (Figures 5 a, 5b and 5c). Anti-
TNFα agents showed a significantly better efficacy in preventing clinical, endoscopic and 
severe endoscopic POR in a nonselected CD population (OR: 0.324, 95% CI: 0.158–0.664, P 
= 0.002; OR: 0.225, 95% CI: 0.124–0.409, P < 0.001; and OR: 0.248, 95% CI: 0.070–0.877, 
P = 0.031, respectively). The overall heterogeneity was the highest in the analysis of severe 
endoscopic POR (I
2 
= 55.3%; P = 0.062) (Supplementary Table 3).  
 
Safety analysis 
Six of the fourteen studies reported the rate of adverse events (AEs) of postoperative 
preventive treatments [10, 17-19, 25, 28], while three studies reported the rate of SAEs [17-
19]. No significant difference was observed in AE or SAE rates between the anti-TNFα and 
the conventional treatment groups (OR: 0.86, 95% CI: 0.457-1.617, P = 0.639; and OR: 
1.018, 95% CI: 0.641-1.617, P = 0.94, respectively) (Supplementary Figure 7a and 7b). 
 
Risk of bias assessment 
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Risk of bias assessments of the included studies are shown in Supplementary Figure 8. In 
RTCs, random sequence generation was described in sufficient detail in only 40% and 
allocation concealment in only 30% of the articles. Four studies were open-label studies; they 
therefore carried a high risk of bias due to lack of blinding among participants and personnel. 
In four studies, the assessment of outcomes was unblinded or not described accurately. All of 
the studies were judged as being low risk with regard to the item of incomplete outcome, 
excepting the study of Scapa, which was only published in abstract form. All of the studies 
were judged as being free from other potential sources of bias, excepting the study of Scapa 
(unclear risk of bias) and the study of Fukushima (high risk of bias). As for selective 
reporting, we failed to identify half of the studies in trial protocol databases; they were 
therefore considered to have an unclear risk of bias in this regard. 
All of the included observational studies were considered low-risk studies with regard 
to each item, except for assessment of outcome. From this point of view, they were both 
assigned zero stars because none of them detailed blinding for the outcome assessment 
(whether endoscopic operators performing control endoscopies were blinded or not). In the 
study of Auzolle, the comparability of the cohorts of patients could not be judged based on the 
article content. According to our assessment, the included observational studies achieved six 
to eight points out of a maximum of nine. 
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Discussion 
Most of the patients with CD require surgery during their lifetime. Within one year, 80% of 
operated patients develop endoscopic POR. However, there is no widely accepted consensus 
on the prevention of POR, though the issue has been approached through multiple meta-
analyses and a Cochrane review in recent years. 
In our meta-analysis, we used the most up-to-date data from 14 clinical studies, of 
which most were RCTs. Most of the included studies compared the efficacy of anti-TNFα 
agents to non-biological comparators in preventing clinical, endoscopic, severe endoscopic 
and histological POR. The minority compared the efficacy of ADA and IFX. We made an 
effort to synthesize all the possible comparisons in our meta-analysis. 
Firstly, we evaluated the efficacy of anti-TNFα agents compared to non-biological 
comparators. Based on our results, anti-TNFα agents were significantly more effective in 
preventing clinical, endoscopic, severe endoscopic and histological POR. Our findings 
confirm results from previous meta-analyses [20-22].
 
As part of our comparison, we analysed 
the efficacy of anti-TNFα agents compared to the thiopurine-treated group. Anti-TNFα agents 
proved to be better in all kinds of analysed POR prevention, but their superiority over 
thiopurines could only be detected in the case of endoscopic POR. 
Secondly, we performed a direct, head-to-head comparison between ADA and IFX in 
preventing endoscopic POR. We found that the efficacy of these two anti-TNFα agents is 
nearly the same, thus confirming previously performed indirect comparisons [21, 48]. 
Thirdly, uniquely in the literature so far, we aimed to identify groups of patients who 
will benefit most from a preventive anti-TNFα treatment after resection. We therefore 
compared the anti-TNFα agents to controls in the high-risk and nonselected CD patient 
subgroups. The analysis indicated that nonselected patients enjoy the benefits of preventive 
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anti-TNFα treatment with respect to clinical, endoscopic and severe endoscopic POR as well, 
independently from risk stratification. 
Our meta-analysis has several strengths worth highlighting. A high number (1,124) of 
operated CD patients were enrolled in the analyses, and most of the included studies were 
RCTs. This is the first meta-analysis involving subgroup analyses on patient selection upon 
risk stratification. A head-to-head comparison between IFX and ADA was also possible, 
which confirmed previous indirect comparisons. Today, mucosal healing is considered as one 
of the hardest endpoints in predicting long-term clinical success in IBD [49]. Closely related 
to this, we examined the efficacy of anti-TNFα treatment compared to conventional therapies 
with respect to the prevention of histological POR.  
However, we are aware that our findings suffer from several limitations. First, we 
could not investigate the effect of co-treatments used in the different treatment arms. Second, 
the follow-up period in the included studies ranged between six and 36 months, although most 
reported the results at one year. Finally, we could not evaluate the effect of new biologics 
(e.g., VDZ and ustekinumab) on POR prevention, since there have been just very few results 
published on this field. 
 In summary, the results from our meta-analysis confirm that early initiated 
postoperative anti-TNFα treatment is currently the most effective therapeutic choice in 
preventing the continuum of histological, endoscopic, and clinical POR without increasing the 
frequency of AEs. Our findings suggest that it is unnecessary to select patients after intestinal 
resection based on risk factors since even nonselected populations can benefit from early 
initiated prophylactic anti-TNFα therapy postoperatively. Both IFX and ADA are equally 
effective in preventing endoscopic POR. Further large RCTs are needed to confirm and 
strengthen our results.  
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Table 1 Baseline characteristics of patients in the studies analyzed 
 
 
 
RCT: randomized controlled trial; IFX: infliximab; AZA: azathioprine; NA: non-available; 6-MP: 6-mercaptopurin; anti-TNFα: anti-tumor necrosis factor alpha; ADA: adalimumab; MTX: methotrexate; 
MSN: mesalamine; PLAC: placebo; 
a
 mean +/-SD; 
b
 median (range); 
c 
median (IQR); 
d
 mean (range); 
e
 median (25%; 75%); 
f
 median (min – max.); * years; ** months; VDZ: vedolizumab; MZD: 
metronidazole 
 
Author  
(year) 
Study type 
(number of 
centers) 
Drug (n) 
Male 
(%) 
Age at surgery 
(years) 
Disease 
duration 
Smoking 
n (%) 
Perianal 
disease 
n (%) 
≥1 previous 
resections 
n (%) 
Disease location at surgery 
n (%) 
Disease behavior at 
surgery  
n (%) 
L1 L2 L3 L4 B1 B2 B3 
Armuzzi et al. 
(2013) 
RCT (1) 
IFX (11) 7 (64) 34 (24-37)
c
 24 (15-81)
c**
 5 (46) 5 (46) 4 (36) NA NA NA NA NA NA 7 (64) 
AZA (11) 8 (73) 32 (21-45)
c
 24 (12-54)
c**
 5 (46) 6 (55) 4 (36) NA NA NA NA NA NA 5 (46) 
Auzolle et al. 
(2018) 
prospective 
cohort (1) 
anti-TNFα (66) NA NA NA NA NA NA NA NA NA NA NA NA NA 
AZA/6-MP (40) NA NA NA NA NA NA NA NA NA NA NA NA NA 
De Cruz et al. 
(2015) 
RCT (18) 
ADA (28) 11 (39) 39 (30-49)
c
 11 (6-18)
c**
 10 (36) NA 12 (43) 17 (61) 2 (7) 9 (32) 0 (0) 3 (11) 8 (29) 17 (61) 
AZA/6-MP (73) 40 (55) 33 (24-45)
c
 8 (3-18)
c**
 28 (38) NA 21 (29) 34 (47) 4 (5) 35 (48) 0 (0) 5 (7) 16 (22) 52 (71) 
Fukushima et al 
(2018) 
RCT (13) 
IFX (19) 17 (90) 36.6 (19–55)* 5.5 (1–11)* 5 (26) NA 2 (11) 4 (21) 3 (16) 12 (63) 0 (0) 1 (5) 13 (68) 5 (26) 
MSN (19) 13 (68) 37.6 (23–74)* 6.2 (1–11)* 2 (11) NA 4 (21) 7 (37) 1 (5) 11 (58) 0 (0) 0 (0) 11 (58) 8 (42) 
Kotze et al. 
(2014) 
retrospective 
(7) 
ADA (37) 21 (57) 33.6 ± 12.1
a
 84 (2-300)
f**
 4 (11) 9 (24) 12 (32) 13 (35) 4 (11) 20 (54) 0 (0) 4 (11) 18 (49) 15 (41) 
IFX (59) 38 (64) 31.1 ± 10.9
a
 82 (2-240)
f**
 9 (15) 22 (37) 25 (42) 21 (36) 2 (3) 36 (61) 0 (0) 1 (2) 33 (56) 25 (42) 
Lopez-Sanroman 
et al. (2017) 
RCT (24) 
ADA (45) 19 (42) 35 (30-40)
c
 8.1
b*
 11 (24) 4 (9) 3 (7) 26 (58) 0 (0) 19 (42) 2 (4) 0 (0) 0 (0) 20 (44) 
AZA (39) 23 (59) 37 (31-47)
c
 7.3
b*
 9 (23) 8 (21) 3 (8) 23 (59) 0 (0) 16 (41) 3 (8) 0 (0) 0 (0) 11 (28) 
Regueiro at al. 
(2009) 
RCT (1) 
IFX (11) 5 (46) 43 (28; 49)
e
 13 (1; 19)
e*
 5 (46) NA 11 (100) 2 (18) 0 (0) 9 (82) 0 (0) 0 (0) 4 (25) 12 (75) 
PLAC (13) 3 (23) 32 (26; 45)
e
 9 (2; 12)
e*
 1 (8) NA 13 (100) 3 (23) 0 (0) 10 (77) 0 (0) 0 (0) 4 (25) 12 (75) 
Regueiro at al. 
(2016) 
RCT (104) 
IFX (147) 77 (52) 35 (26-45)
c
 8.4 ± 8.7
a*
 38 (26) 17 (12) 68 (46) 144 (99) 0 (0) 89 (61) 6 (4) NA NA NA 
PLAC (150) 81 (54) 34 (25-44)
c
 6.4 ± 7.5
a*
 37 (25) 13 (9) 79 (53) 146 (97) 0 (0) 76 (51) 6 (4) NA NA NA 
Savarino at al. 
(2013) 
RCT (1) 
ADA (16) 8 (50) 45 (22-66)
d
 8.4 (1-17)
d*
 9 (56) NA 4 (25) 9 (56) 0 (0) 7 (44) 0 (0) 0 (0) 4 (25) 12 (75) 
AZA (17) 9 (53) 49 (24-69)
d
 7.9 (1-17)
d*
 4 (24) NA 2 (12) 8 (47) 0 (0) 9 (53) 0 (0) 0 (0) 5 (29) 12 (71) 
MSN (18) 8 (44) 46 (25-65)
d
 6.9 (1-18)
d*
 6 (33) NA 5 (29) 8 (44) 0 (0) 10 (56) 0 (0) 0 (0) 4 (22) 14 (78) 
Scapa et al. 
(2015) 
RCT (1) 
ADA (11) NA 30.5 ± 2.3
a*
 NA 1 (9) NA NA NA NA NA NA NA NA NA 
6-MP (8) NA 34.4 ± 2.5
a*
 NA 3 (38) NA NA NA NA NA NA NA NA NA 
Sorrentino at al. 
(2007) 
prospective 
pilot study (1) 
IFX+MTX (7) 4 (57) 36 (23-64)
b
 7 (3-14)
b*
 2 (29) NA 2 (29) 5 (71) 0 (0) 2 (29) 0 (0) NA NA NA 
MSN (16) 11 (69) 40.5 (23-70)
b
 5.5 (1-23)
b*
 4 (25) NA 1 (6) 11 (69) 3 (19) 2 (13) 0 (0) NA NA NA 
Tursi et al. (2014) RCT (1) 
ADA (10) 5 (50) 34.5 (22-39)
b
 48 (6-144)
b*
 2 (20) 4 (40) 3 (30) NA NA NA NA 0 (0) 0 (0) 8 (80) 
IFX (10) 4 (40) 30.5 (20-33)
b
 48 (6-130)
b*
 3 (30) 4 (40) 4 (40) NA NA NA NA 0 (0) 0 (0) 3 (30) 
Yamada et al. 
(2018) 
retrospective 
(1) 
VDZ (22) 8 (36) 25.5 (23.0-30.7)
c*
 9 (2.5-12.0)
c*
 3 (14) 12 (55) 13 (59) 4 (18) 5 (23) 13 (59) 2 (9) 6 (27) 10 (46) 6 (27) 
anti-TNFα (58) 30 (52) 36.0 (28.5-48.5)c* 12 (4.0-18.0)c* 7 (12) 16 (28) 37 (64) 16 (28) 8 (14) 34 (59) 4 (7) 9 (16) 24 (41) 25 (43) 
AZA/6-MP (38) 18 (47) 40.5 (25.0-49.5)
c*
 9 (1.0-15.0)
c*
 4 (11) 6 (16) 17 (45) 14 (37) 5 (13) 19 (50) 4 (11) 4 (11) 11 (29) 23 (61) 
MZD (16) 7 (44) 44.0 (34.7-53.0)
c*
 8 (5.5-18.2)
c*
 1 (6) 8 (50) 8 (50) 6 (38) 4 (25) 6 (38) 0 (0) 3 (19) 6 (38) 7 (44) 
PLAC (69) 34 (49) 41.0(30.0-54.0)
c*
 8 (2.0-19.0)
c*
 15 (22) 11 (16) 46 (67) 18 (28) 18 (28) 29 (45) 1 (1) 17 (25) 23 (33) 29 (42) 
Yoshida et al. 
(2011) 
RCT (1) 
IFX + MSN (15) 11 (73) 36.9 ± 11.6
a
 11.6 ± 8.8
a*
 3 (20) NA 11 (73) 4 (27) 0 (0) 11 (73) 0 (0) NA NA NA 
MSN (16) 12 (75) 32.9 ± 10.2
a
 9.2 ±7.1
a*
 3 (19) NA 10 (63) 4 (25) 0 (0) 12 (75) 0 (0) NA NA NA 
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PRISMA Checklist for Preferred Reporting Items for Systematic Reviews and Meta-Analyses  
Section/topic   #  Checklist item   
Reported 
on page #   
TITLE       
Title   1  Identify the report as a systematic review, meta-analysis, or both.   1 
ABSTRACT      
Structured summary   2  Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, 
participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and 
implications of key findings; systematic review registration number.   
5 
INTRODUCTION      
Rationale   3  Describe the rationale for the review in the context of what is already known.   6-7 
Objectives   4  Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, 
outcomes, and study design (PICOS).   
8 
METHODS       
Protocol and registration   5  Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide 
registration information including registration number.   
8 
Eligibility criteria   6  Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, 
language, publication status) used as criteria for eligibility, giving rationale.   
9  
Information sources   7  Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify 
additional studies) in the search and date last searched.   
8  
Search   8  Present full electronic search strategy for at least one database, including any limits used, such that it could be 
repeated.   
8-9  
Study selection   9  State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, 
included in the meta-analysis).   
9  
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Data collection process   10  Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes 
for obtaining and confirming data from investigators.   
9-10  
Data items   11  List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and 
simplifications made.   
10  
Risk of bias in individual 
studies   
12  Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done 
at the study or outcome level), and how this information is to be used in any data synthesis.   
11 
Summary measures   13  State the principal summary measures (e.g., risk ratio, difference in means).   11-12 
Synthesis of results   14  Describe the methods of handling data and combining results of studies, if done, including measures of consistency 
(e.g., I2) for each meta-analysis.   
11-12 
  
Section/topic   #  Checklist item   
Reported 
on page #   
Risk of bias across studies   15  Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective 
reporting within studies).   
15-16 
Additional analyses   16  Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating 
which were pre-specified.   
10, 12 
RESULTS       
Study selection   17  Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at 
each stage, ideally with a flow diagram.   
12-13  
Study characteristics   18  For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and 
provide the citations.   
 9-10 
Risk of bias within studies   19  Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).   15-16 
Results of individual studies   20  For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each 
intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.   
13-15 
Synthesis of results   21  Present results of each meta-analysis done, including confidence intervals and measures of consistency.   13-15  
Risk of bias across studies   22  Present results of any assessment of risk of bias across studies (see Item 15).   15-16 
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Additional analysis   23  Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).   13-15  
DISCUSSION       
Summary of evidence   24  Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to 
key groups (e.g., healthcare providers, users, and policy makers).   
16-17  
Limitations   25  Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of 
identified research, reporting bias).   
17 
Conclusions   26  Provide a general interpretation of the results in the context of other evidence, and implications for future research.   17-18 
FUNDING       
Funding   27  Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the 
systematic review.   
2  
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Supplementary Table 2 Outcomes of enrolled studies on clinical, endoscopic, severe endoscopic and histological postoperative recurrence 
 
IFX: infliximab; AZA: azathioprine; 6-MP: 6-mercaptopurin; NA: non-available; anti-TNFα: anti-tumor necrosis factor alpha; ADA: adalimumab; MSN: mesalamine; MTX: methotrexat; MZD: metronidazole; PLAC: 
placebo; wks: weeks; eow: every other week; sc: subcutaneously; tid: three times a day; VDZ: vedolizumab 
References 
(year) 
Follow up 
(months) 
Drug regimen (n) 
Clinical 
recurrence (%) 
Endoscopic 
recurrence 
(i2-4) (%) 
Severe endoscopic  
recurrence (i3-4) 
(%) 
Histological 
recurrence (%) 
Armuzzi et al (2013) 12 
IFX: 5 mg/kg at 0, 2. 6. wks, then q8w (11) 1 (9) 1 (9) 0 (0) 2 (18) 
AZA: 2.5 mg/kg/day (11) 1 (10) 4 (40) 1 (10) 8 (73) 
Auzolle et al. (2018) 6-12 
anti-TNFα: NA (66) NA 26 (39) NA NA 
AZA/6MP: NA (40) NA 22 (55) NA NA 
De Cruz et al. (2015) 6 
ADA: 160/80 mg at 0, 2. wks, then 40 mg eow (28) 5 (18) 6 (21) 1 (4) NA 
AZA: 2 mg/kg/day or 6-MP: 1.5 mg/kg/day (73) 16 (22) 33 (45) 6 (8) NA 
Fukushima et al. (2018) 24 
IFX: 5 mg/kg at 0, 2. 6. wks, then q8w (19) 1 (5) 0 (0) 0 (0) 
NA 
MSN: NA (19) 8 (50) 4 (21) 4 (21) 
Kotze et al. (2014) 12 
IFX: NA (59) NA 16 (27) NA NA 
ADA: NA (37) NA 9 (24) NA NA 
Lopez-Sanroman et al 
(2017) 
12 
ADA: 160/80 mg at 0, 2. wks, then 40 mg eow +MZD (45) 7 (16) 19 (42) 5 (14) 
NA 
AZA: 2.5 mg/kg/day + MZD (39) 14 (36) 23 (59) 2 (8) 
Regueiro at al (2009) 12 
IFX: 5 mg/kg at 0, 2. 6. wks, then q8w (11) 0 (0) 1 (9) 1 (9) 3 (27) 
PLAC: (13) 5 (39) 11 (85) 7 (54) 11 (85) 
Regueiro at al. (2016) 18 
IFX: 5 mg/kg q8w (147) 19 (13) 33 (22) 11 (19) NA 
PLAC: (150) 30 (20) 77 (51) 48 (81) NA 
Savarino at al. (2013) 24 
ADA: 160/80 mg at 0, 2. wks, then 40 mg eow (16) 1 (6) 0 (0) 0 (0) NA 
AZA: 2 mg / kg / day (17) 12 (71) 8 (47) 3 (18) NA 
MSN: 3 g / day (18) 9 (50) 7 (39) 3 (17) NA 
Scapa et al. (2015) 6 
ADA: 160/80 mg at 0, 2. wks, then 40 mg eow (11) NA 1 (9) NA NA 
6-MP: 1.5 mg/kg/day (8) NA 4 (50) NA NA 
Sorrentino at al (2007) 24 
IFX: 5 mg/kg at 0, 2. 6. wks, then q8w + MTX: 10 mg/wk (7) 0 (0) 0 (0) 0 (0) 
NA 
MSN: 800 mg tid (16) 5 (31) 12 (75) NA 
Tursi et al.(2014) 12 
IFX: 5 mg/kg at 0, 2. 6. wks, then q8w (10) 1 (10) 2 (20) 1 (10) 
NA 
ADA: 160/80 mg at 0, 2. wks, then 40 mg eow (10) 1 (10) 1 (10) 0 (0) 
Yamada et al. (2018) 6-12 
VDZ: NA (22)  10 (46) 15 (68) NA 15 (68) 
Anti TNFα: NA (58) 18 (31) 13 (22) NA 15 (26) 
AZA/6-MP: NA (38) 14 (37) 14 (37) NA 19 (50) 
MZD: NA (16) 10 (63) 5 (31) NA 2 (13) 
PLAC: NA (69) 29 (42) 26 (38) NA 16 (23) 
Yoshida et al. (2011) 36 
IFX+MSN: 5 mg/kg q8w (15) 2 (13) 3 (21) NA NA 
MSN (16) 4 (25) 13 (81) NA NA 
Table S_2
Click here to download Supplementary Material (for online publication): Supplementary_Table_2.docx
 Supplementary Table 3 The results of test for heterogeneity. Chi-square statistic (Q-value) with degree of freedom (df), 
associated p-value and I
2 
values are shown.  
 
 Clinical recurrence Endoscopic recurrence Severe endoscopic recurrence Histological recurrence 
Q value df P I
2 
(%) Q value df P I
2 
(%) Q value df P I
2 
(%) Q value df P I
2 
(%) 
Biologics vs. Non-biological comparators 
ADA subgroup 6.70 2 0.04 70.2 4.09 3 0.25 26.6 3.27 2 0.19 38.9 - - - - 
ANTI-TNFα subgroup 1.65x10-17 0 1 0 0.16 1 0.69 0 - - - - 4.70x10-15 0 1 0 
IFX subgroup 5.37 5 0.37 6.9 8.64 5 0.12 42.1 0.57 3 0.90 0 0.02 1 0.89 0 
Overall 14.61 9 0.10 38.4 17.75 11 0.09 38.0 9.27 6 0.16 35.3 5.43 2 0.07 63.2 
Biologics vs. Non-biological comparators 
High-risk subgroup 8.90x10
-3
 1 0.92 0 0.23 1 0.63 0 0.04 1 0.84 0 - - - - 
Nonselected subgroup 13.70 7 0.06 48.9 17.51 9 0.04 48.6 8.95 4 0.06 55.3 - - - - 
Overall 14.61 9 0.10 38.4 17.75 11 0.09 38.0 9.27 6 0.16 35.3 - - - - 
Biologics vs. Thiopurines 
ADA subgroup 6.70 2 0.04 70.2 4.09 3 0.25 26.6 3.27 2 0.19 38.9 - - - - 
ANTI-TNFα subgroup 1.65x10-17 0 1 0 0.16 1 0.69 0 - - - - - - - - 
IFX subgroup 9.73x10
-19
 0 1 0 5.50x10
-15
 0 1 0 0 0 1 0 - - - - 
Overall 9.26 4 0.05 56.8 5.25 6 0.51 0 3.65 3 0.30 17.8 - - - - 
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